Cellares has successfully raised $355 million in funding to advance its cancer treatment technology. The funding round aims to support the development of innovative cell therapy methods to combat blood cancer.

Mar 24, 2025•5 months ago

Amount Raised

$355 Million

San FranciscoBiotechnologyManufacturing

Description

Cellares, a biotech startup based in Bridgewater, N.J., has secured $355 million in funding to further its groundbreaking approach to cancer treatment. The company specializes in developing customized cell therapy solutions that utilize patients' own white blood cells. By advancing their technology, Cellares aims to overcome the challenges of producing these therapies at scale. This significant funding will enhance their capabilities in an important and evolving area of medical research.

Company Information

Company

Cellares

Location

345 ALLERTON AVE

San Francisco, California, United States

About

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech